Who Should Not Get Stem Cell Therapy?

Published September 07, 2026

Stem cell therapy is not appropriate for every patient. Physicians generally exclude people with active cancer, uncontrolled bleeding disorders, active infection near the injection site, pregnancy, or joints with severe, bone-on-bone cartilage loss. A physician-led evaluation — history, imaging review, and lab screening — is what determines whether a specific case fits the current evidence and safety profile, not a marketing claim or a product name.

What This Means

"Contraindication" is a clinical term for a condition or situation where a given procedure is expected to carry more risk than benefit, or where the evidence doesn't support its use. Stem cell–based orthobiologic procedures — using a patient's own cells, most often from bone marrow or fat tissue — have a specific set of these exclusions. Some are absolute (the procedure should not be performed at all). Others are relative (the physician weighs the risk against the individual's overall health and goals).

Candidacy

Good candidates are typically adults with joint, tendon, or ligament pain who have tried and not gotten adequate relief from conservative measures — physical therapy, activity modification, anti-inflammatory medication — and who have imaging showing a structural problem that regenerative procedures are plausibly suited to, such as early-to-moderate osteoarthritis or a chronic tendon injury (Zhang, 2024).

Poor candidates include people with:

Active cancer or a recent cancer history. Growth-factor and cell-based procedures are generally avoided in patients with active malignancy because the biological signals involved in tissue repair overlap with pathways that can support tumor growth.

Pregnancy. The effects of these procedures on a fetus have not been studied, so pregnancy is regarded as an exclusion.

Uncontrolled bleeding disorders or therapeutic anticoagulation that can't be safely paused. Bone marrow or fat harvesting and image-guided injection both carry bleeding risk.

Active infection, anywhere in the body but especially near the planned injection site. Introducing cells or a needle into an area with active infection risks seeding that infection into the joint or tissue.

Severe, end-stage joint damage. When cartilage is gone and bone is contacting bone, a cell-based injection has little tissue left to support, and joint replacement is usually the more appropriate conversation.

Uncontrolled diabetes or other unmanaged systemic disease. Poor glycemic control impairs healing and raises infection risk for any injection-based procedure.

Clinical Evaluation

An evaluation for regenerative orthobiologic care should include a musculoskeletal and neurological exam, review of prior imaging (X-ray, MRI, or both), a relevant lab and medication history, and ultrasound imaging assessment when appropriate. The goal is to identify which structure is generating the symptoms and whether the available evidence supports a regenerative approach for that specific structure and stage of disease — before any product or procedure is discussed.

Available Options

For patients who are excluded from stem cell–based procedures, or who simply want to compare options, conventional and mainstream alternatives include:

Physical therapy and structured exercise programs — first-line for most joint and tendon pain.

Oral or topical anti-inflammatory medication, used short-term under medical supervision.

Corticosteroid injections, which can reduce inflammation and pain for weeks to months but are typically limited in frequency due to cartilage effects with repeated use.

Viscosupplementation (hyaluronic acid injections), an option for some knee osteoarthritis cases.

Platelet-rich plasma (PRP), another autologous orthobiologic option with a different mechanism and evidence base than stem cell procedures.

Surgical options, including arthroscopy or joint replacement, for structural damage that has progressed beyond what any injection-based approach can address.

Benefits, Limitations and Risks

In a multi-center registry of 2,372 patients receiving autologous, MSC-based orthopedic procedures, serious adverse events were uncommon, but the study also documented the realistic range of complications associated with the injection and harvest process itself, including infection and post-procedure pain (Centeno et al., 2016). Separately, regulators have documented serious harm from unapproved cell products offered outside a physician-led evaluation process, including permanent vision loss after an eye injection and a spinal tumor following a spinal cord injection (U.S. Food and Drug Administration, n.d.).

These are not the same setting or the same product category, and outcomes depend heavily on how and where a procedure is performed, who is performing it, and whether the patient was appropriately screened. Regenerative orthobiologic procedures are not without risk, results are not guaranteed, and they are not a substitute for a structural repair that only surgery can provide.

What the Evidence Shows

The evidence base does support some specific claims. A 2024 systematic review and meta-analysis of randomized controlled trials found that mesenchymal stem cell injections outperformed placebo for pain relief and function in knee osteoarthritis at 12-month follow-up, with no statistically significant difference in adverse events between groups (Zhang, 2024).

The evidence does not establish that these procedures regrow lost cartilage, that they work equally well for every joint or every stage of disease, or that any specific clinic's product or protocol produces the results seen in a research setting. The only stem cell products currently FDA-approved in the United States are hematopoietic (blood-forming) stem cells derived from cord blood, used for specific blood and immune system conditions — not the orthobiologic, MSK-focused procedures discussed in this article, which remain investigational outside of FDA-regulated clinical trials (U.S. Food and Drug Administration, n.d.).

Recovery / Next Steps

If a physician determines someone is not currently a candidate, that's rarely a permanent answer. Some exclusions are temporary — an active infection resolves, anticoagulation is adjusted with a prescriber's involvement, blood sugar is brought under better control — and the case can be re-evaluated later. For others, particularly end-stage joint damage or active cancer, a different care pathway is the more honest conversation, and a physician-led practice should say so plainly rather than offer a procedure it doesn't expect to help.

Orlando Considerations

Florida does not require health insurance to cover orthobiologic stem cell procedures for musculoskeletal conditions, and most Orlando-area practices offering them, including PrimeCell, operate on a cash-pay basis. The number of clinics offering "stem cell" procedures in the Orlando market varies widely in what they actually offer and how they screen patients. A pre-procedure medical evaluation — not just a consultation about pricing — is a reasonable baseline to expect from any practice before a procedure is scheduled.

Frequently Asked Questions

Can I still be a candidate if I have diabetes?

It depends on how well controlled it is. Well-managed diabetes is not an automatic exclusion, but uncontrolled blood sugar raises infection risk and impairs healing, so a physician will typically want it addressed first.

Does age disqualify someone?

Age alone is not a standard exclusion. What matters more is the stage of joint or tissue damage, overall health, and other conditions present — an evaluation looks at the whole picture rather than a birthdate.

What happens during the pre-procedure evaluation?

Typically a physical and neurological exam, a review of prior imaging or new imaging if needed, a medication and health history, and sometimes ultrasound imaging, used to confirm which structure is involved and whether a regenerative approach is reasonable for it.

Is there ever a condition where no clinic should offer this, regardless of how it's marketed?

Yes. Active cancer, pregnancy, uncontrolled bleeding disorders, and active infection at the injection site are regarded as exclusions across reputable practices, not a matter of one clinic's preference.

If I'm excluded now, can that change later?

Often, yes. Conditions like an active infection or poorly controlled blood sugar can improve with management, after which a physician can re-evaluate candidacy. Structural exclusions, like bone-on-bone joint damage, are less likely to change.

This article is for general education and does not replace an individualized medical evaluation. Regenerative orthobiologic procedures discussed here are investigational outside FDA-approved clinical trials and are not FDA-approved for any specific musculoskeletal condition. Individual results vary. Regenerative options are discussed only after a physician-led medical evaluation.

Medically reviewed by Kenny Chantasi, DO.

References

Centeno, C. J., Al-Sayegh, H., Freeman, M. D., Smith, J., Murrell, W. D., & Bubnov, R. (2016). A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. International Orthopaedics, 40(8), 1755–1765. https://doi.org/10.1007/s00264-016-3162-y

Mayo Clinic. (n.d.). Stem cells: What they are and what they do. Mayo Foundation for Medical Education and Research. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117

National Institutes of Health, Stem Cell Information. (n.d.). Stem cell clinical trials & other information. U.S. Department of Health and Human Services. https://stemcells.nih.gov/clinical-trial-info

U.S. Food and Drug Administration. (n.d.). Patient and consumer warning about potential serious risks of harm following use of unapproved products from human cells or tissues. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products

Zhang, B. (2024). Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 15, Article 1366297. https://doi.org/10.3389/fendo.2024.1366297

Last medically reviewed: September 07, 2026

If you've had joint or tendon pain without a clear answer on whether a regenerative option fits your case, that's what a PrimeCell evaluation is for. Schedule a consultation and bring any prior imaging or records you have.

Related reading

• What Are the Side Effects of Stem Cell Therapy?
• Is Stem Cell Therapy Legal in the US?
• How Long Is Recovery After Stem Cell Therapy?
• How Do You Know If You're a Good Candidate for Regenerative Medicine?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.